Abbott Half-Year Report 2023

Abbott Financial Results

• Second-quarter GAAP diluted EPS of $0.78 and adjusted diluted EPS of $1.08, which excludes specified items.
• Projected full-year 2023 diluted EPS on a GAAP basis of $3.02 to $3.22.
• Projected full-year adjusted EPS of $4.30 to $4.50 remains unchanged but reflects an increased outlook for the underlying base business offset by a lower forecasted earnings contribution from COVID-19 testing-related sales.
• Abbott now projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, to be in the low double-digits2 and COVID-19 testing-related sales of approximately $1.3 billion.

SECOND-QUARTER BUSINESS OVERVIEW
Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as the COVID-19 pandemic has shifted to an endemic state, resulting in significantly lower demand for COVID-19 tests.